TherapeuticsMD, Inc. (TXMD)

NMS – Real Time Price. Currency in USD

1.98

+0.03 (1.54%)

Market open: May 13, 2026, 9:30 AM EDT

30.03.2026

TherapeuticsMD Announces Full Year 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.

12.11.2025

TherapeuticsMD Announces Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.

Videos

No Data

There is no data to display

Press releases

30.03.2026

TherapeuticsMD Announces Full Year 2025 Financial Results

12.11.2025

TherapeuticsMD Announces Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.

TherapeuticsMD, Inc. (TXMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videos

No Data

Press releases

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videos

No Data

Press releases

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Search stocks

TherapeuticsMD, Inc. (TXMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videos

No Data

Press releases

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videos

No Data

Press releases

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results